Literature DB >> 2703181

Predictive value of cone margins and post-cone endocervical curettage with residual disease in subsequent hysterectomy.

N Husseinzadeh1, I Shbaro, T Wesseler.   

Abstract

In 51 of 106 patients (48%) residual disease was identified in hysterectomy specimens performed following cervical conization. Invasive squamous cell carcinoma was found in one patient in spite of clear cone margins. Thirty-nine of sixty-three patients (62%) with cervical intraepithelial neoplasia (CIN) involving the inner (endocervical) margin of the cone biopsy had residual disease. When both the inner margin and post-cone endocervical curettage (ECC) were involved, residual disease was present in 24 of 30 (80%) hysterectomy specimens. When the inner margins of the cone were involved with CIN-III and the post-cone ECC was negative, 36% of hysterectomy specimens contained residual disease compared to 88% when post-cone ECC was positive. These findings indicate that post-cone endocervical curettage has significant predictive value with respect to the presence or absence of residual disease in patients with CIN involving the inner margins of the cervical cone.

Entities:  

Mesh:

Year:  1989        PMID: 2703181     DOI: 10.1016/0090-8258(89)90551-9

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

1.  Role of high risk-human papilloma virus test in the follow-up of patients who underwent conization of the cervix for cervical intraepithelial neoplasia.

Authors:  Jeong-Yeol Park; Jaeman Bae; Myong Cheol Lim; So Yi Lim; Dong-Ock Lee; Sokbom Kang; Sang-Yoon Park; Byung-Ho Nam; Sang-Soo Seo
Journal:  J Gynecol Oncol       Date:  2009-06-29       Impact factor: 4.401

2.  Nucleolar organiser regions in adenocarcinoma in situ and invasive adenocarcinoma of the cervix.

Authors:  J F Darne; S V Polacarz; E Sheridan; D Anderson; R Ginsberg; F Sharp
Journal:  J Clin Pathol       Date:  1990-08       Impact factor: 3.411

3.  The value of endocervical curettage at time of cervical cone biopsy.

Authors:  C O Spann; T Brown; J E Kennedy; C R Wheeless
Journal:  J Natl Med Assoc       Date:  1993-02       Impact factor: 1.798

4.  Absence of dysplasia in the excised cervix by a loop electrosurgical excision procedure in the treatment of cervical intraepithelial neoplasia.

Authors:  Aeli Ryu; Kyehyun Nam; Sooho Chung; Jeongsik Kim; Haehyeog Lee; Eunsuk Koh; Donghan Bae
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

5.  Predicting persistent/recurrent disease in the cervix after excisional biopsy.

Authors:  Sanjay M Ramchandani; Karen L Houck; Enrique Hernandez; John P Gaughan
Journal:  MedGenMed       Date:  2007-04-30

6.  The accuracy of cervical cancer and cervical intraepithelial neoplasia diagnosis with loop electrosurgical excisional procedure under colposcopic vision.

Authors:  Komsun Suwannarurk; Sutatip Bhamarapravati; Yuthadej Thaweekul; Karicha Mairaing; Yenrudee Poomtavorn; Junya Pattaraarchachai
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

7.  A human papillomavirus (HPV)-16 or HPV-18 genotype is a reliable predictor of residual disease in a subsequent hysterectomy following a loop electrosurgical excision procedure for cervical intraepithelial neoplasia 3.

Authors:  Woo Dae Kang; U Chul Ju; Seok Mo Kim
Journal:  J Gynecol Oncol       Date:  2015-10-08       Impact factor: 4.401

8.  Factors that influence persistence or recurrence of high-grade squamous intraepithelial lesion with positive margins after the loop electrosurgical excision procedure: a retrospective study.

Authors:  Menghan Zhu; Yuan He; Jan Pa Baak; Xianrong Zhou; Yuqing Qu; Long Sui; Weiwei Feng; Qing Wang
Journal:  BMC Cancer       Date:  2015-10-20       Impact factor: 4.430

9.  Residual disease and risk factors in patients with high-grade cervical intraepithelial neoplasia and positive margins after initial conization.

Authors:  Yunfeng Fu; Chen Chen; Suwen Feng; Xiaodong Cheng; Xinyu Wang; Xing Xie; Weiguo Lü
Journal:  Ther Clin Risk Manag       Date:  2015-05-21       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.